DPP-4 inhibitors surface

A new class of oral anti-sugar drugs known as DPP-4 inhibitors is quietly emerging in the fast-growing market for diabetes drugs, and several pharmaceutical giants are making it a standardtreatment for hyperglycemiaRecently, at the American Diabetes Association's annual conference on technology, Mercado, AstraZeneca incand Baxter-Squibb published their findings, which showed that THE combination of DPP-4 inhibitors and the traditional anti-sugar drug metformin could have better clinical results than the use of metformin aloneFor Mercatom, the results of the study are significantJanuvia, the world's first and only listed DPP-4 inhibitor, is from researchers in MercadonJanuvia went public in the U.Slast OctoberIn April, Januvia and metformin (commodity name Janumet) were approved for listing in the United StatesMercado's research was published at the right time at this important diabetes academic exchangeMeanwhile, the DPP-4 inhibitor saxagliptin, developed jointly by Persimmon and AstraZeneca, has reached its final sprint stageTo this end, the two companies also need enough clinical data to lay a solid foundation for the future market fate of this product, after all, favorable clinical research results can not only promote the FDA and other national drug agencies as soon as possible for the product to market the green light, but also allow such new products to be welcomed by clinicians and more competitive marketMercado's results were based on a 54-week clinical study of 762 patientsIn the end, there was a statistical improvement in the value of glycated hemoglobin (HbA
1c) in patients taking Januvia/metformin alone compared to those who took metformin aloneSimilarly, a 24-week study of 743 patients conducted by 100-time Meisie Squibb and AstraZeneca found significant statistical differences in the use of metformin in the study product sesame as monolith As a result, a senior manager in charge of research and development in Mersadon has said that the initial treatment of diabetes with a single drug is often inadequate, and that many patients need a more comprehensive combination of drugs Indeed, DPP-4 inhibitors have their own unique advantages over traditional sugar-lowering drugs in the past, allowing them to achieve a double mechanism to lower blood sugar, while inhibiting the total amount of glucose produced by the liver glycogen, while it also promotes the pancreatic to produce more insulin At this point, DPP-4 inhibitors are still positioned to treat type 2 diabetes, because the biggest problem for people with this type of diabetes is not being able to secrete enough insulin to break down blood sugar in their bodies However, Januvia is not currently a first-line drug for the treatment of type 2 diabetes, and the FDA has positioned its compound formulation sits above patients who have no control over blood sugar in both Januvia and metformin To this end, Mersadon has submitted new clinical data to the FDA and has submitted an application to convert januvia/metformin compound formulations to first-line medications